TNDM — Tandem Diabetes Care, Inc. stock price, charts and financials

QT75Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
22.33
-0.05-0.22%
TNDMQT75Tandem Diabetes Care, Inc.·NASDAQ
22.33-0.22%
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E-EPS (ttm)-1.40Insider Own1.31%Shs Outstand68.53MPerf Week14.77%
Market Cap1.53BForward P/E176.21EPS next Y0.13Insider Trans-0.02%Shs Float62.92MPerf Month45.61%
Enterprise Value2.21BPEG-EPS next Q-Inst Own-Short Float20.84%Perf Quarter21.17%
Income-63.49MP/S1.47EPS this Y51.93%Inst Trans-Short Ratio5.54Perf Half Y18.16%
Sales1.04BP/B11.74EPS next Y118.87%ROA-5.49%Short Interest13.12MPerf YTD1.82%
Book/sh-P/C-EPS next 5Y-ROE-45.97%52W High29.58 -24.52%Perf Year55.52%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-4.67%52W Low9.96 124.25%Perf 3Y-31.14%
Dividend Est.-EV/EBITDA-Sales past 3/5Y8.21% 15.26%Gross Margin56.01%Volatility9.85% 7.05%Perf 5Y-79.41%
Dividend TTM-EV/Sales2.12EPS Y/Y TTM4.76%Oper. Margin-4.13%ATR (14)1.38Perf 10Y-71.23%
Dividend Ex-Date-Quick Ratio2.65Sales Y/Y TTM9.26%Profit Margin-6.08%RSI (14)72.61Recom2.38
Dividend Gr. 3/5Y-Current Ratio3.18EPS Q/Q55.22%SMA2024.27%Beta1.52Target Price30.12
Payout0.00%Debt/Eq5.67Sales Q/Q5.56%SMA5031.33%Rel Volume2.16Prev Close22.38
Employees2,500LT Debt/Eq2.74EarningsNov 04SMA20016.91%Avg Volume2.52MPrice22.33
IPO DateNov 14, 2013Option/ShortYes / YesEPS/Sales Surpr.32.38% 2.83%Net Debt/EBITDA-22.32Volume5,434,643Change-0.22%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedRBC CapitalOutperform$30$26
Aug-07-26ReiteratedCanaccord GenuityBuy$35$40
Jul-28-26ResumedUBSNeutral$22$18
Jun-23-26DowngradeDeutsche BankBuyHold$16
Jun-01-26UpgradeWells FargoEqual WeightOverweight$45$27
May-27-26ReiteratedGoldman SachsNeutral$24$21
May-11-26ReiteratedBarclaysOverweight$56$55
May-08-26ReiteratedMizuho SecuritiesNeutral$22$24
Apr-24-26ReiteratedRedburn Partners$36$45
Mar-19-26UpgradeTruist SecuritiesHoldBuy
Latest News
Aug-07-26
Aug-06-26
Jul-16-26
Jul-07-26
Jul-01-26
Jun-30-26
Jun-23-26
Company

Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,0411,015940
Cost of Goods Sold Incl. D&A458484451
Gross Profit583531490
Selling, General and Administrative Excl. Other439434390
Research and Development187175199
Other Operating Expense
000
Operating Income-43-78-99
Interest Expense887
Unusual Expense
Non-Operating Income (Expense)-10-11415
Net Income Before Taxes-61-200-92
Income Taxes344
Consolidated Net Income-63-205-96
Net Income From Continuing Operations-63-205-96
Net Income-63-205-96
EPS (Recurring)-0.93-3.04-1.47
EPS (Basic, Before Extraordinaries)-0.93-3.04-1.47
EPS (Diluted)-0.93-3.04-1.47
EBITDA-31-175-99
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
Price To Sales Ratio1.461.452.49
Gross Margin56.0052.3252.13
Operating Margin-4.13-7.68-10.53
Net Margin-6.05-20.20-10.21
Shares Outstanding686765
Market Capitalization1,5181,4732,341
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$30.98$25.09$19.19$13.29$7.40 Close Price0.00K62.93K125.86K188.79K251.72KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kyrillos Jean-ClaudeEVP & Chief Operating OfficerJul 15 '26Option Exercise0.003,636031,741Jul 17
McGroddy-Goetz KathleenDirectorMay 21 '26Option Exercise0.008,759026,612May 22
ROBERTSON REBECCA BDirectorMay 21 '26Option Exercise0.008,759022,542May 22
Allen Dickother: Chair EmeritusMay 21 '26Option Exercise0.008,759028,146May 22
Howell Peyton RDirectorMay 21 '26Option Exercise0.008,759029,836May 22
Malagueira Joao Paulo FalcaoDirectorMay 21 '26Option Exercise0.008,759022,458May 22
TWOMEY CHRISTOPHER JDirectorMay 21 '26Option Exercise0.008,759024,434May 22
Cha MyoungilDirectorMay 21 '26Option Exercise0.008,759022,458May 22
Sodhi RajwantDirectorMay 21 '26Option Exercise0.008,759024,280May 22
Morrison SusanEVP & Chief Admin. OfficerMay 15 '26Option Exercise0.009,523051,414May 19
Sheridan John FPRESIDENT & CEOMay 15 '26Option Exercise0.0051,1890170,051May 19
Vosseller LeighEVP & CHIEF FINANCIAL OFFICERMay 15 '26Option Exercise0.0013,495051,829May 19
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICERMay 15 '26Option Exercise0.0010,572048,171May 19
Carpenter RickEVP & Chief Technology OfficerMay 15 '26Option Exercise0.008,774032,859May 19
Gasser Elizabeth AnneEVP, Chief Strategy OfficerMay 15 '26Option Exercise0.0010,26709,937May 19
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.